Cantargia

Share Issue/Capital Change • Dec 30, 2020

Press release

Cantargia AB 556791-6019 30 December 2020

New number of shares and votes in Cantargia

The number of shares and votes in Cantargia AB (publ) has changed due to the recently completed directed share issue (for further information, see the company's press releases on 15 and 16 December 2020). Through the share issue, the number of shares and votes in Cantargia increased by 9,100,548. Today, on the last trading day of the month, there are in total 100,192,737 shares and votes in Cantargia.

For further information, please contact: Göran Forsberg, CEO Telephone: +46 (0)46-275 62 60 E-mail: goran.forsberg@cantargia.com

This is information that Cantargia AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 30 December 2020.

About Cantargia

Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for lifethreatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04, is being studied clinically as combination therapy with chemotherapy or immune therapy with a primary focus on non-small cell lung cancer and pancreatic cancer. Positive interim data from the combination with chemotherapy show a higher response rate than would be expected from chemotherapy alone. Cantargia's second project, the antibody CAN10, addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.